✦ LIBER ✦

Cost-Effectiveness and Cost-Utility Analysis of Belimumab for the Treatment of Patients with Systemic Lupus Erythematosus in Portugal

✍ Scribed by Gouveia, M.; Borges, M.; Augusto, M.; Costa, J.; Treur, M.; Lopes, S.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Utility Analysis (CUA) of Belimumab

✍ Walczak, J.; Kopel, J.; Sołtys, E.; Dziurda, D. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Assessment of the Economic Impact of Bel

✍ Turchetti, G.; Pierotti, F.; Palla, I.; Stragliotto, E.; Porcasi, R.; Pippo, L. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN93 Treatment of Well-Differentiated P

✍ J. Walczak; M. Garbacka; J. Zawieja; P. Prząda-Machno; J. Kroc 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost effectiveness and cost utility anal

✍ Soto, H.; Pizarro, M.; Botello, B.S.; Almeida, E. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

The cost-effectiveness of screening and

✍ A. J. Sutton; W. J. Edmunds; M. J. Sweeting; O. N. Gill 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB

Estimating the cost-effectiveness of bel

✍ Lee, K.K.C.; Azmi, S.; Wu, D.B.C.; Goh, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB